Tim Smith

New research into the use of ustekinumab compared to other treatments for psoriasis sheds light on risk for outpatient infections.

New research into the nursing home CMS rating system suggests that a revision may improve the public’s information access.

New research was found on alcohol consumption as a modifiable risk factor in dementia, in a study out of South Korea.

An interview with Victoria Barrio, MD, and Fabiana Castro Porto Silva Lopes, MD, about the Society for Pediatric Dermatology and its efforts to address diversity in the dermatology field.

A recent study highlighted new information on racial disparities in health care for Black and Hispanic pediatric patients with atopic dermatitis.

New research into egg, peanut allergies and sensitization raised questions about allergy incidence rates and early exposure.

A list of the top stories covered this week in the dermatology field, with data on breakthroughs, new research, and advanced treatment options.

In recent research into alopecia areata treatments, selective JAK1 inhibition was tested as a means for restoring hair growth.

New research demonstrated that 5-fluorouracil and microneedling in conjunction showed stronger results for the 19 participants than tacrolimus monotherapy as a treatment for vitiligo.

This week, the FDA announced that 27 lots of levothyroxine sodium oral solution, used for hypothyroidism, were being recalled due to potentially being subpotent.

In a population-based cohort study in China, researchers found that a healthy lifestyle contributed to slower declines in memory for older adults.

A recent research letter identified a correlation between mRNA vaccines for COVID-19 and cases of chronic spontaneous urticaria, although the connection requires further study.

In a recent analysis of 6 trials examining the use of dupilumab, the drug was found to be useful alongside concomitant TCS for patients with erythrodermic atopic dermatitis.

New research into risk factors for pediatric liver transplant patients indicated that atopy and allergy may follow a transplant and are more common among females and younger patients.

The FDA announced that Banana Boat Hair & Scalp Sunscreen was being recalled voluntarily by its company due to risk of benzene exposure to consumers.

New research into atopic dermatitis treatment indicated that topical JAK inhibitors were safe and effective, although more research is needed regarding adverse effects.

In new research, an association between food allergies and atopic dermatitis was highlighted, suggesting the need for further research.

New research, comparable with that of the NAVIGATE trial, was conducted and showed strong results for the use of guselkumab for psoriasis patients.

In a recent study, DLE patients responded well to topical niacinamide 2% and 4% as adjuvant therapy, with strong results and few side effects.

In this recent study, mental health conditions associated with alopecia areata were assessed by the study’s investigators.

The latest HCPLive interview segment with Karan Lal, DO, discussing his views on what can go wrong during cosmetic procedures.

A new interview segment with Karan Lal, DO, in which he explores the benefits and drawbacks of dermatology offices versus medical spas.

Recent phase 3 clinical trial data explains response patterns of rheumatoid arthritis patients to baracitinib.

The house dust mite allergen extract was approved by the FDA for treating adolescents with immunotherapy.

Recent findings indicated that patients with new-onset psoriasis may see positive results from switching to secukinumab treatment.

New research connected dupilumab levels to OSD in atopic dermatitis patients, indicating a contribution to the development of the condition.

This recent analysis highlighted an association between anxiety disorder and psoriasis in both children and adult patients.

New research on updadacitinib’s use for atopic dermatitis patients suggests the drug may be effective for hand eczema.

New research has helped to validate a predictive design model created to identify those most at risk for developing fibromyalgia.

A recent study on allergies to methylchloroisothiazolinone or methylisothiazolinone, with findings suggesting that European regulations may have diminished sensitivity rates.